Evidence map›Paper›PMID 37055826›Full record

ReviewCancer cell international2023

The NF-ĸB p50 subunit generated by KPC1-mediated ubiquitination and limited proteasomal processing, suppresses tumor growth.

Yelena Kravtsova-Ivantsiv, Gilad Goldhirsh, Ciprian Tomuleasa, Eli Pikarsky, Aaron Ciechanover

Open access · goldAbstract readReview
In one paragraph

Review in Cancer cell international, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed, 1 pooled it
0.9field-weighted citation impact, top 25% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 1 synthesis or guideline pooled it, 6 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Review
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 4 institutions in 3 countries.

Yelena Kravtsova-Ivantsiv *The Rappaport Faculty of Medicine and Research Institute and the Rappaport Technion Integrated Cancer Center (R-TICC), Technion-Israel Institute of Technology, P.O. Box 9649, 3109601, Haifa, Israel. yelenaiv@technion.ac.il.
Gilad Goldhirsh *The Rappaport Faculty of Medicine and Research Institute and the Rappaport Technion Integrated Cancer Center (R-TICC), Technion-Israel Institute of Technology, P.O. Box 9649, 3109601, Haifa, Israel.
Ciprian TomuleasaDepartment of Hematology-Medfuture Research Center for Advanced Medicine, Iuliu Hatieganu University of Medicine and Pharmacy, Cluj-Napoca, Romania.
Eli PikarskyThe Lautenberg Center for Immunology and Cancer Research, Institute for Medical Research Israel-Canada (IMRIC), Hebrew University-Hadassah Medical School, 9112000, Jerusalem, Israel.
Aaron CiechanoverThe Rappaport Faculty of Medicine and Research Institute and the Rappaport Technion Integrated Cancer Center (R-TICC), Technion-Israel Institute of Technology, P.O. Box 9649, 3109601, Haifa, Israel. aaroncie@technion.ac.il.
Rappaport Family Institute for Research in the Medical Sciences · ILConcern Foundation · USIuliu Hațieganu University of Medicine and Pharmacy · ROTechnion – Israel Institute of Technology · IL

Funding

Structural-functional MRI Studies of Memory in MCI &ADK23AG022509 · NIA · MASSACHUSETTS GENERAL HOSPITAL · PI DICKERSON, BRADFORD C · 2003 to 2007
$783k
a Professorship funded by the Israel Cancer Research Fund (ICRF) USA 2032219Dr. Miriam and Sheldon G. Adelson Medical Research Foundation 86493811Israel Science Foundation 2030744Romanian 344 National Ministry of Research, Innovation, and Digitalization PCE 225/09.03.2021The Israel Precision Medicine Partnership (IPMP) 2070233
6 · The paper itself

Abstract

Nuclear factor-ĸB (NF-ĸB) is an important transcriptional regulator of key cellular processes, including cell cycle, immune response, and malignant transformation. We found that the ubiquitin ligase Kip1 ubiquitination-promoting complex subunit 1 (KPC1; also known as Ring finger protein 123 - RNF123) stimulates ubiquitination and limited proteasomal processing of the p105 NF-ĸB precursor to generate p50, the active subunit of the heterodimeric transcription factor. KPC1 binds to the ankyrin repeats' (AR) domain of NF-ĸB p105 via a short binding site of 7 amino acids-968-WILVRLW-974. Though mature NF-ĸB is overexpressed and constitutively active in different tumors, we found that overexpression of the p50 subunit, exerts a strong tumor suppressive effect. Furthermore, excess of KPC1 that stimulates generation of p50 from the p105 precursor, also results in a similar effect. Analysis of transcripts of glioblastoma and breast tumors revealed that excess of p50 stimulates expression of many NF-ĸB-regulated tumor suppressive genes. Using human xenograft tumor models in different immune compromised mice, we demonstrated that the immune system plays a significant role in the tumor suppressive activity of p50:p50 homodimer stimulating the expression of the pro-inflammatory cytokines CCL3, CCL4, and CCL5 in both cultured cells and in the xenografts. Expression of these cytokines leads to recruitment of macrophages and NK cells, which restrict tumor growth. Finally, p50 inhibits the expression of the programmed cell death-ligand 1 (PDL1), establishing an additional level of a strong tumor suppressive response mediated by the immune system.

Indexed as

ChemokinesKPC1NF-ĸB p50PDL1PROTACProteasomeTumor-suppressionUbiquitin ligase

Identifiers

PMID37055826
PMCPMC10100387
OpenAlexW4365451982

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.